与我们的专家分析师一起探索CRISPR Therapeutics（NASDAQ：CRSP）的激动人心的世界

查看下面的视频，以获得对市场趋势和潜在投资机会的宝贵见解！*使用的股票价格是2025年1月29日的价格。

In this Motley Fool Scoreboard episode, we'll be delving into the exciting world of CRISPR Therapeutics (NASDAQ:CRSP) with our expert analysts. Join them as they discuss the latest market trends and highlight potential investment opportunities.

在这个Motley愚人记分板情节中，我们将与我们的专家分析师一起研究CRISPR Therapeutics（NASDAQ：CRSP）的激动人心的世界。加入他们讨论最新市场趋势并突出潜在的投资机会时。

But first, let's see what one analyst is recommending for investing $1,000 right now.

但是首先，让我们看看一位分析师现在建议投资1,000美元的建议。

Where to invest $1,000 right now?

现在在哪里投资1,000美元？

Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

我们的分析师团队刚刚透露了他们认为现在要购买的10种最佳股票。

See the full ranking now.

立即查看完整的排名。

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now … and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Motley Fool Stock Advisor分析师团队刚刚确定了他们认为现在可以购买投资者的10个最佳股票……而CRISPR Therapeutics并不是其中之一。裁员的10个股票可能会在未来几年产生怪物回报。

Consider when Nvidia made this list on April 15, 2005 … if you invested $1,000 at the time of our recommendation, you'd have $736,343!

考虑一下NVIDIA在2005年4月15日列出此列表时……如果您在建议时投资了1,000美元，您将有736,343美元！

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002. Don't miss out on the latest top 10 list, available when you join Stock Advisor.

Stock Advisor为投资者提供了易于遵循的成功蓝图，包括有关建立投资组合的指南，分析师的定期更新以及每月两个新的股票选秀权。自2002年以来，股票顾问服务已经超过了标准普尔500指数的回报。当您加入股票顾问时，请不要错过最新的前10名列表。

Get started investing with our analyst team today.

立即开始与我们的分析师团队进行投资。

Now, let's get started with CRISPR Therapeutics.

现在，让我们开始从CRISPR Therapeutics开始。

One analyst is recommending investors buy CRISPR Therapeutics stock. Despite a recent surge of over 100% in 2024, the biotech's stock price is still down 70% from its all-time high reached in November 2021.

一位分析师建议投资者购买CRISPR Therapeutics股票。尽管最近在2024年增长了100％以上，但生物技术的股票价格仍比2021年11月的历史最高水平下降了70％。

After a strong fourth-quarter earnings report in February, enthusiasm for CRISPR has soared. The company exceeded analysts' expectations for both earnings and revenue, and it also raised its outlook for the full year.

在2月份获得了第四季度的大量收益报告之后，对CRISPR的热情激增。该公司超出了分析师对收入和收入的期望，并且还提高了整整一年的前景。

CRISPR is a leading developer of next-generation gene therapies, using the CRISPR-Cas9 technology to treat serious illnesses. The company's main focus is on treating blood disorders such as beta-thalassemia and sickle cell disease. Its flagship product, an experimental treatment for beta-thalassemia called bentradicimab, is currently in Phase 3 testing.

CRISPR是下一代基因疗法的主要开发商，使用CRISPR-CAS9技术治疗严重疾病。该公司的主要重点是治疗血液疾病，例如β-综合性贫血和镰状细胞疾病。它的旗舰产品是一种用于Bentradicimab的β-地中海贫血的实验治疗方法，目前正在第三阶段测试中。

Earlier this month, CRISPR announced that it had achieved promising results in a mid-stage clinical trial of bentradicimab in treating sickle cell disease. The company observed a complete response rate of 50% in patients with beta-thalassemia who had received at least 12 months of treatment with bentradicimab.

本月初，CRISPR宣布，它在Bentradicimab的中期临床试验中取得了有希望的结果，以治疗镰状细胞疾病。该公司观察到β-甲性甲性疾病患者的完全缓解率为50％，他们接受了至少12个月的Bentradicimab治疗。

In the third quarter, CRISPR posted a net loss of $108.7 million, compared to analysts' estimate of $117.5 million. The company reported earnings per share of $0.40, whereas analysts expected $0.37. Revenue for the period amounted to $140.9 million, exceeding analysts' projections of $133 million.

在第三季度，CRISPR的净亏损为1.087亿美元，而分析师的估计为1.175亿美元。该公司报告的每股收益为0.40美元，而分析师预计0.37美元。该期间的收入为1.409亿美元，超过了分析师的预测1.33亿美元。

For the full year, CRISPR now anticipates a net loss in the range of $360 million to $390 million, narrower than the prior outlook of $400 million to $430 million. Analysts had estimated a net loss of $372 million. The biotech also raised its revenue forecast for the year to a band of $540 million to $570 million, up from the previous projection of $490 million to $520 million. Analysts had estimated revenue of $541 million.

在整整一年中，CRISPR现在预计净亏损在3.6亿至3.9亿美元之间，比先前的4亿至4.3亿美元的前景窄。分析师估计净亏损为3.72亿美元。该生物技术还将当年的收入预测提高到了5.4亿美元的乐队，从上一年的预测4.9亿美元提高到5.7亿美元。分析师估计收入为5.41亿美元。

Despite the promising results and optimistic outlook, one analyst remains cautious on CRISPR stock. Here's why.

尽管有令人鼓舞的结果和乐观的前景，但一位分析师仍然对CRISPR股票保持谨慎。这就是原因。

Now playing video

现在播放视频

portion

部分

Hello, and welcome to this edition of Motley Fool Top Buys. I'm Karl Thiel, and I'll be joined by one of The Motley Fool's expert analysts as we take a closer look at one stock that could be a promising addition to your portfolio.

您好，欢迎使用此版本的Motley傻瓜购买。我是卡尔·泰尔（Karl Thiel），我将加入Motley Fool的一位专家分析师之一，因为我们仔细研究了一张股票，这可能是您投资组合的一个有希望的补充。

We'll also be highlighting the ten best stocks to buy right now, according to The Motley Fool's analyst team. But first, let's delve into the world of CRISPR Therapeutics (NASDAQ:CRSP) with Keith Speights.

据Motley Fool的分析团队称，我们还将重点介绍现在购买的十个最佳股票。但是首先，让我们与基思·斯佩斯（Keith Speights）一起研究CRISPR Therapeutics（NASDAQ：CRSP）的世界。

Now, CRISPR has been a hot stock in 2024, surging more than 100%. However, it's still down 70% from its all-time high, which it reached in November 2021.

现在，CRISPR在2024年一直是热门股票，飙升超过100％。但是，它的历史最高水平仍然下降了70％，它于2021年11月达到。

After a strong fourth-quarter earnings report in February, enthusiasm for CRISPR has reached new heights. The biotech beat expectations for both earnings and revenue, and it also raised its outlook for the full year.

在2月份获得了第四季度的大量收益报告之后，对CRISPR的热情已经达到了新的高度。 Biotech击败了对收入和收入的期望，并且还提高了整整一年的前景。

CRISPR is a leading developer of next-generation gene therapies, using the CRISPR-Cas9 technology to treat serious illnesses. The company's main focus is on treating blood disorders such as beta-

CRISPR是下一代基因疗法的主要开发商，使用CRISPR-CAS9技术治疗严重疾病。该公司的主要重点是治疗血液疾病，例如β-